Pharmanutra S.p.A. (BIT:PHN)
Italy · Delayed Price · Currency is EUR 72.20
+1.30 (1.83%)
Sep 25, 2026, 5:35 PM CET
Pharmanutra Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 142.77 | 131.69 | 115.5 | 100.2 | 82.72 | 68.11 |
Other Revenue | 0.93 | 0.47 | 0.65 | 0.5 | 0.34 | 0.03 |
| 143.7 | 132.16 | 116.15 | 100.71 | 83.06 | 68.14 | |
Revenue Growth | 17.94% | 13.78% | 15.33% | 21.24% | 21.89% | 20.04% |
Cost of Revenue | 71.43 | 65.37 | 56.91 | 52.09 | 41.14 | 35.99 |
Gross Profit | 72.27 | 66.79 | 59.24 | 48.62 | 41.92 | 32.15 |
Selling, General & Admin | 36.98 | 32.71 | 26.67 | 22.55 | 17.19 | 12.12 |
Other Operating Expenses | 0.92 | 1.41 | 1.81 | 0.43 | 0.34 | 0.34 |
Operating Expenses | 41.63 | 37.69 | 31.88 | 25.6 | 18.84 | 13.86 |
Operating Income | 30.64 | 29.1 | 27.36 | 23.02 | 23.07 | 18.3 |
Interest Expense | -0.56 | -0.66 | -1.06 | -0.8 | -0.06 | -0.02 |
Interest & Investment Income | 0.53 | 0.52 | 0.68 | 0.32 | 0.13 | 0.15 |
Currency Exchange Gain (Loss) | -0.13 | -0.08 | -0.04 | 0.08 | -0.03 | - |
Other Non Operating Income (Expenses) | 0.82 | 1.64 | 0.77 | 1.17 | 0.34 | 0.4 |
EBT Excluding Unusual Items | 31.3 | 30.52 | 27.71 | 23.79 | 23.45 | 18.83 |
Gain (Loss) on Sale of Assets | -0 | -0 | -0.27 | -0.03 | -0.03 | -0.02 |
Legal Settlements | -0.33 | -0.33 | -0.27 | -0.5 | - | - |
Pretax Income | 30.97 | 30.19 | 27.16 | 23.26 | 23.42 | 18.81 |
Income Tax Expense | 10.31 | 10.27 | 10.61 | 10.43 | 8.37 | 5.04 |
Earnings From Continuing Operations | 20.67 | 19.92 | 16.55 | 12.83 | 15.05 | 13.77 |
Minority Interest in Earnings | 0.08 | 0.09 | 0.06 | - | - | - |
Net Income | 20.74 | 20 | 16.61 | 12.83 | 15.05 | 13.77 |
Net Income to Common | 20.74 | 20 | 16.61 | 12.83 | 15.05 | 13.77 |
Net Income Growth | 22.78% | 20.44% | 29.43% | -14.73% | 9.27% | -2.13% |
Shares Outstanding (Basic) | 10 | 10 | 10 | 10 | 10 | 10 |
Shares Outstanding (Diluted) | 10 | 10 | 10 | 10 | 10 | 10 |
Shares Change | -0.12% | -0.16% | -0.67% | -0.05% | -0.09% | - |
EPS (Basic) | 2.17 | 2.09 | 1.73 | 1.33 | 1.56 | 1.42 |
EPS (Diluted) | 2.17 | 2.09 | 1.73 | 1.33 | 1.56 | 1.42 |
EPS Growth | 22.92% | 20.63% | 30.29% | -14.69% | 9.37% | -2.13% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 15.02 | 16.43 | 16.17 | -1.16 | -8.69 | 15.43 |
Free Cash Flow Per Share | 1.57 | 1.71 | 1.68 | -0.12 | -0.90 | 1.59 |
Dividend Per Share | 1.200 | 1.200 | 1.000 | 0.850 | 0.800 | 0.710 |
Dividend Growth | 20.00% | 20.00% | 17.65% | 6.25% | 12.68% | 5.97% |
Gross Margin | 50.29% | 50.54% | 51.00% | 48.28% | 50.47% | 47.18% |
Operating Margin | 21.32% | 22.02% | 23.55% | 22.86% | 27.78% | 26.85% |
Profit Margin | 14.44% | 15.14% | 14.30% | 12.74% | 18.12% | 20.21% |
Free Cash Flow Margin | 10.46% | 12.43% | 13.92% | -1.15% | -10.46% | 22.64% |
EBITDA | 33.2 | 31.82 | 30.87 | 25.44 | 24.22 | 19.3 |
EBITDA Margin | 23.10% | 24.08% | 26.58% | 25.26% | 29.16% | 28.33% |
D&A For EBITDA | 2.56 | 2.72 | 3.51 | 2.42 | 1.15 | 1.01 |
EBIT | 30.64 | 29.1 | 27.36 | 23.02 | 23.07 | 18.3 |
EBIT Margin | 21.32% | 22.02% | 23.55% | 22.86% | 27.78% | 26.85% |
Effective Tax Rate | 33.28% | 34.03% | 39.06% | 44.83% | 35.74% | 26.78% |
Revenue as Reported | 145.15 | 133.97 | 116.91 | 101.96 | 83.39 | 68.84 |